Javascript must be enabled to continue!
Systematic mutational mapping reveals optimal amyloid formation for RIPK function
View through CrossRef
Abstract
Amyloid formation, typically associated with neurodegeneration, can also serve essential biological functions. RIPK1 and RIPK3 kinases assemble functional amyloids via their RHIM domains to drive necrosome formation and necroptosis. Here, we systematically map the sequence-function relationship of these domains using deep mutagenesis combined with massively parallel assays that directly report on amyloid nucleation and necroptotic signaling. Analysis of ∼3,000 mutations across RIPK1 and RIPK3 reveals that both proteins rely on a conserved aliphatic tetrad to nucleate amyloids, but diverge mechanistically: RIPK3 nucleation is largely driven by this core interface, whereas RIPK1 requires a second aliphatic surface to achieve efficient nucleation. Cross-species comparisons with mutational atlases from mouse RIPKs show conservation of these principles, underscoring their evolutionary selection. Strikingly, functional outcomes depend on finely balanced nucleation: variants that either reduce or enhance amyloid formation impair necroptosis. Consistently, human population genetics indicates that such variants are extremely rare, suggesting evolutionary optimization of the RHIM domain at a “sweet-spot” of amyloid propensity required for signaling. By linking quantitative mutational landscapes to functional amyloid assembly, this work uncovers how evolution has tuned the amyloid propensity of RIPKs to enable robust cell death signaling. These insights not only advance our understanding of amyloid biology but also provide a framework for therapeutic modulation of necroptosis and for engineering synthetic amyloids with tailored activities.
Title: Systematic mutational mapping reveals optimal amyloid formation for RIPK function
Description:
Abstract
Amyloid formation, typically associated with neurodegeneration, can also serve essential biological functions.
RIPK1 and RIPK3 kinases assemble functional amyloids via their RHIM domains to drive necrosome formation and necroptosis.
Here, we systematically map the sequence-function relationship of these domains using deep mutagenesis combined with massively parallel assays that directly report on amyloid nucleation and necroptotic signaling.
Analysis of ∼3,000 mutations across RIPK1 and RIPK3 reveals that both proteins rely on a conserved aliphatic tetrad to nucleate amyloids, but diverge mechanistically: RIPK3 nucleation is largely driven by this core interface, whereas RIPK1 requires a second aliphatic surface to achieve efficient nucleation.
Cross-species comparisons with mutational atlases from mouse RIPKs show conservation of these principles, underscoring their evolutionary selection.
Strikingly, functional outcomes depend on finely balanced nucleation: variants that either reduce or enhance amyloid formation impair necroptosis.
Consistently, human population genetics indicates that such variants are extremely rare, suggesting evolutionary optimization of the RHIM domain at a “sweet-spot” of amyloid propensity required for signaling.
By linking quantitative mutational landscapes to functional amyloid assembly, this work uncovers how evolution has tuned the amyloid propensity of RIPKs to enable robust cell death signaling.
These insights not only advance our understanding of amyloid biology but also provide a framework for therapeutic modulation of necroptosis and for engineering synthetic amyloids with tailored activities.
Related Results
Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers
Brain MRI signatures across sex and CSF Alzheimer’s disease biomarkers
Abstract
The relationship between cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease and neurodegenerative effects is not fully understood. This study inves...
Reasons for undergoing amyloid imaging among cognitively unimpaired older adults
Reasons for undergoing amyloid imaging among cognitively unimpaired older adults
AbstractObjectivesPreclinical Alzheimer’s disease (AD) clinical trials screen cognitively unimpaired older adults for biomarker criteria and disclose their results. We examined whe...
The question of strains in AA amyloidosis
The question of strains in AA amyloidosis
Abstract
The existence of transmissible amyloid fibril strains has long intrigued the scientific community. The strain theory originates from prion disorders, but here, w...
Pathological and neurophysiological outcomes of seeding human-derived tau pathology in the APP-KI NL-G-F and NL-NL mouse models of Alzheimer’s Disease
Pathological and neurophysiological outcomes of seeding human-derived tau pathology in the APP-KI NL-G-F and NL-NL mouse models of Alzheimer’s Disease
AbstractThe two main histopathological hallmarks that characterize Alzheimer’s Disease are the presence of amyloid plaques and neurofibrillary tangles. One of the current approache...
Protein amyloid aggregate: Structure and function
Protein amyloid aggregate: Structure and function
Abstract
Protein amyloid aggregation has been widely observed to occur and plays important roles in both physiological processes and pathological diseases. Remark...
SRS295 - Assessing the effect of oxidative stress on pig kidneys during normothermic machine perfusion
SRS295 - Assessing the effect of oxidative stress on pig kidneys during normothermic machine perfusion
Abstract
Introduction
Ischaemia reperfusion injury (IRI) is a detrimental part of organ transplantation, damaging previou...
Leveraging speech and artificial intelligence to screen for early Alzheimer’s disease and amyloid beta positivity
Leveraging speech and artificial intelligence to screen for early Alzheimer’s disease and amyloid beta positivity
Abstract
Early detection of Alzheimer’s disease is required to identify patients suitable for disease-modifying medications and to improve access to non-pharmacologi...
Aβ remotely and locally facilitates Alzheimer’s disease tau spreading
Aβ remotely and locally facilitates Alzheimer’s disease tau spreading
Abstract
Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-beta plaques initiated approximately 2 decades before the symptom onset followed by...

